

FIG.1




FIG.2

3/36




FIG.3

4/36




FIG. 4A




FIG. 4B




FIG.4C





FIG.4D


6(a)/36

FIG. 5A



PLGpZS encapsulating PBS


FIG. 5B



PLGpS encapsulating PBS


6(b)/36

FIG.6A



PLGpZS encapsulating Antigen

FIG.6B



PLGpS encapsulating Antigen

7 / 36

Comparative Release of Hin-47 from
PLG, PLGpZS and PLGpS Microspheres
(μg Hin-47/mg Microspheres)




FIG.7A

8 / 36

% Cumulative Release Comparison of Hin-47 from
PLG, PLGpZS and PLGpS Microspheres





FIG. 7B

9/36

Anti-Hin-47 IgG Antibody Responses
from PLG, PLGpZS and PLGpS Microspheres
(Day 10, 24, 35, 45 and 60)
Subcutaneous Immunizations (Day 1 and 35)




FIG.8A

Anti-Hin-47 IgG Antibody Responses
from Physical Mixes of PLG/PBS Microspheres
and Hin-47 (Day 10, 24, 35, 45 and 60)
Subcutaneous Immunizations (Day 1 and 35)





FIG.8B

Anti-Hin-47 IgG Subtypes
Low Dose Groups (Day 35 and 60)
Subcutaneous Immunizations (Day 1 and 35)




FIG.8C





FIG.9A

13/ 36



Anti-Hin-47 IgG Subtypes
(Day 56 and 78)
Oral Immunizations (Day 1, 7, 14 and 57)




FIG.9B

14 / 36




FIG. 9C

15 / 36




FIG.10A





FIG.10B

18 / 36



19 / 36




FIG.10E

Anti-Flu X-31 IgG Antibody Responses
from PLG, PLGpZS and PLGpS Microspheres
(Day 21 and 33)
Subcutaneous Immunization (Day 1)




FIG.11

21/36




FIG.12

22 / 36

HAI titres from Sera (Day 21, 42 and 57)
 Subcutaneous Immunization (single dose)
 PLGpS/Flu (A-Texas) and BAY R1-005 Formulations
 Dose - Flu = 10 µg, HA = 3.50 µg




FIG.13




FIG.14A

24/ 36

Anti-Flu (A/Johannesburg) IgG Antibody Responses
Single Dose-Subcutaneous Study
PLGpS Microparticles and Flu (trivalent) Formulations
(Day 21, 42 and 57)




FIG.14B

25 / 36

Anti-flu (B/Harbin) IgG Antibody Responses
 Single Dose-Subcutaneous Study
 PLGpS Microparticles and Flu (trivalent) Formulations
 (Day 21, 42 and 57)




FIG.14C

HAI titres (A/Texas) from Sera (Day 21, 42 and 57)
 Subcutaneous Immunization (single dose)
 PLGpS Microparticles and Flu (trivalent) Formulations
 Low Dose - Flu = 10 µg, Total HA = 2.35 µg
 High Dose - Flu = 21.2 µg, Total HA = 5.00 µg




FIG.15A

HAI titres (A/Johannesburg) from Sera (Day 21, 42 and 57)
 Subcutaneous Immunization (single dose)
 PLGpS Microparticles and Flu (trivalent) Formulations
 Low Dose - Flu = 10 µg, Total HA = 2.35 µg
 High Dose - Flu = 21.2 µg, Total HA = 5.00 µg




FIG.15B

28/36

HAI titres (B/Harbin) from Sera (Day 21, 42 and 57)
 Subcutaneous Immunization (single dose)
 PLGpS Microparticles and Flu (trivalent) Formulations
 Low Dose - Flu = 10 µg, Total HA = 2.35 µg
 High Dose - Flu = 21.2 µg, Total HA = 5.00 µg





FIG.15C



30/36




FIG.17A

31 / 36

Anti-Tbp2 IgG Subtype Responses (Day 55)
Subcutaneous Immunizations (Day 1 ,28 and 43)




FIG.17B

32 / 36

Anti-Tbp2 IgG Antibody Responses
(Day 14, 27, 42 and 55)
Intranasal Immunizations (Day 1, 28 and 43)




FIG.18

33 / 36




FIG.19




FIG.20

Protection Study - Challenge with *H. Pylori* (Day 85) on Mice Immunized Subcutaneously with PLGpS/rUrease Microparticle Formulations




FIG. 21A

36 / 36

Protection Study - Challenge with H. Pylori (Day 85) on Mice Immunized Orally with
PLGpS/rUrease Microparticle Formulations




FIG.21B